ABCL — AbCellera Biologics Share News
0.000.00%
- $3.75bn
- $2.99bn
- $75.13m
Brief: AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million
Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
AbCellera Q1 revenue more than doubles, beats estimates
Brief: AbCellera Q1 Revenue USD 8.3 Million Vs. IBES Estimate USD 5.86 Million
AbCellera Q4 revenue beats expectations
Brief: AbCellera Q4 Revenue USD 44.9 Million Vs. IBES Estimate USD 6.06 Million
U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
AbCellera rises as it starts mid-stage trial for menopause drug
Brief: Abcellera Announces First Patients Dosed In Phase 2 Portion Of Its Phase 1/2 Clinical Trial Of Abcl635 For The Treatment Of Vasomotor Symptoms Due To Menopause
Brief: Abcellera And Bruker Reach Global Settlement Of Patent Litigation
AbCellera Biologics Q3 revenue smashes estimates
Brief: AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
Brief: AbCellera Q2 Revenue USD 17.1 Million Vs. IBES Estimate USD 6.12 Million
Brief: Abcellera Receives Authorization From Health Canada To Initiate Phase 1 Clinical Trial Of ABCL575
Brief: AbCellera Receives Authorization From Health Canada To Initiate The Phase 1 Clinical Trial Of Abcl635 For Vasomotor Symptoms Due To Menopause
Brief: Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit
Abcellera Biologics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: AbCellera Q1 Revenue USD 4.2 Million Vs. IBES Estimate USD 7.53 Million